T 1423/22 (Renal disease/IDEXX) 23-07-2024

Reasons for the Decision

Main request (patent as granted)

Admittance of a fresh ground for opposition

1. In the statement of grounds of appeal, the appellant raised, for the first time, an objection based on the ground for opposition under Article 100(c) EPC (see also section II. above). The respondent argued that this ground for opposition should not be admitted into the appeal proceedings.

2. According to decision G 10/91 of the Enlarged Board of Appeal (OJ 1993, 420, Headnote 3), fresh grounds for opposition may only be considered in appeal proceedings with the approval of the patentee. Since in this case the respondent, i.e. the patentee, opposed the admittance of the above-identified objection into the appeal proceedings (see point 1. above), there is no scope for considering this objection.

3. The board therefore decided not to take into consideration the objection raised on appeal based on the ground for opposition under Article 100(c) EPC.

Admittance of an objection based on document D8 (Article 12 RPBA)

4. Document D8 was filed with the notice of opposition, i.e. within the time limit pursuant to Article 99(1) EPC, and therefore forms part of the opposition proceedings. The opposition division therefore had no discretionary power under Article 114(2) EPC not to admit this document.

5. However, in the opposition proceedings document D8 was not used to substantiate any objections that had been raised. The appellant's assertion in the statement of grounds of appeal that the claimed method lacked an inventive step in view of the disclosure in either of documents D1 or D6 combined with the disclosure in document D8 therefore represents an amendment of the appellant's case that may only be admitted into the appeal proceedings at the discretion of the board (Article 12(2) and (4) RPBA).

6. The appellant did not provide any reasons why it had not submitted this objection until the appeal proceedings. In fact, since document D8 had been submitted with the notice of opposition and a similar objection had been made in relation to the disclosure of document D2, the board cannot see any reason why the appellant had not raised the objection based on document D8 in the opposition proceedings, nor can it identify any particular circumstances of the appeal case that would justify the admittance of the objection on appeal. Contrary to the appellant's allegation, document D8, a research article, does not reflect common general knowledge.

7. Consequently, and in line with the provisions under Article 12(6) RPBA stipulating that a board must not admit, inter alia, objections or evidence which should have been submitted in the proceedings leading to the decision under appeal, the board decided not to admit into the appeal proceedings the objection based on document D8.

Admittance of document E1 and the line of argument under the heading "Digression" (Article 12 RPBA)

8. With the statement of grounds of appeal, the appellant submitted a new document (E1) and a new line of argument based on this document, under the heading "Digression", in which it questioned whether, as considered in the decision under appeal, Examples 6 and 7 of the patent demonstrated an improvement when estimating the glomerular filtration rate (GFR) using the product of the measured free symmetrical dimethylarginine (SDMA) and serum creatinine (sCr) concentration values compared to using either measured concentration value alone. The appellant did not provide any reasons why it had not submitted this objection until the appeal stage.

9. It was asserted in the patent that Examples 6 and 7 do demonstrate an improvement in the estimation of the GFR as a result of combining sCr and SDMA values by multiplication compared to using either value alone (see paragraphs [0143] and [0148] of the patent). Consequently, document E1 and the objection under the heading "Digression" do not constitute a response to a new development of the case triggered by the decision under appeal; rather, they should have been presented in the opposition proceedings.

10. In view of this and in line with the provisions under Article 12(6) RPBA (see point 7. above), the board decided not to admit document E1 or the objection under the heading "Digression" into the appeal proceedings.

Inventive step (Article 100(a) and Article 56 EPC) - claim 1

11. The claim concerns a method for estimating the GFR in an animal subject and comprises the technical steps of measuring the concentration of free SDMA and that of sCr in a blood sample from the subject ("step (i)" and "step (ii)"), and a step of "comparing a value resulting from an equation comprising the product of the concentration of creatinine and the concentration of SDMA to one or more standard values that correlate to glomerular filtration rate in the animal subject" ("step (iii)").

12. Step (iii) of the claimed method hence relates to a mathematical operation (multiplication of two measured values together) and to a mental act (comparing the value of the resulting product to one or more standard values), i.e. is non-technical. The claim therefore consists of a mixture of technical and non-technical features.

13. Documents D1 and D6 were proposed as the closest prior art.

Document D1 as the closest prior art

14. Document D1 discloses measuring concentration levels of both sCr and SDMA in dogs and demonstrates their correlation with the GFR measured by iohexol clearance (see the figure and the second to fourth paragraphs). The document concludes that SDMA "correlates well with GFR ... and might be a useful addition to sCr in the assessment of renal function" (see the last paragraph).

15. The claimed method differs from that proposed in document D1 in step (iii) (see point 11. above), i.e. in that a value resulting from an equation comprising the product of the sCr and SDMA concentration values is compared to one or more standard values that correlate to the GFR in the animal subject. This was not contested.

16. However, the appellant contested that this distinguishing feature, which was non-technical, contributed to the technical character of the claimed method.

17. If a claimed invention consists of a mixture of technical and non-technical features, as is the case with the present claim 1 (see points 11. and 12. above), and has a technical character, i.e. solves a technical problem, all of the features that contribute to that technical character, i.e. that solve a technical problem by providing a technical effect, are to be taken into account in the assessment of inventive step, even if these features are non-technical per se (T 641/00, Headnote 1, and Reasons 5 and 6; G 1/19, OJ EPO 2021, A77, Reasons 140).

18. The claimed method has a technical character as it solves the technical problem of estimating the GFR, a clinical parameter relevant in renal diseases, based on measuring the blood concentrations of two markers (SDMA and sCr). Step (iii), which is non-technical, contributes to solving this technical problem, together with measurement steps (i) and (ii), because the GFR estimated for an animal subject is determined by the recited calculation of a product of measured SDMA and sCr concentration values and a comparison of this product to one or more standard values that correlate to the GFR in the animal subject.

19. It is noted that the claim lacks an explicit link of step (iii) to the actual estimation of the GFR as it does not recite that by comparing the product of the sCr and SDMA concentration values to one or more standard values that correlate to the GFR in the animal subject the value of the correlated GFR is read out, and that this correlated GFR represents the GFR estimated for the animal subject. However, despite this deficiency, the skilled person immediately understands from the wording of the claim that the comparison to standard values, which correlate to a particular GFR, directly and necessarily leads to the estimation of the GFR in the animal subject for which the blood markers were measured. The missing explicit link of how the steps of the claimed method result in the estimation of the GFR can thus be implicitly understood from the method steps.

20. Indeed, if the claimed method were to be interpreted as nothing more than a mere comparison of the product of the measured sCr and SDMA concentration values to one or more standard values that correlate with the GFR in the animal subject, without linking this comparison to the estimated GFR in the animal subject, the purpose of the claimed method - estimating the GFR in an animal subject - would not be achieved.

21. However, since this purpose of the claimed method is expressed in the claim as a functional feature, not achieving this effect by the steps of the claimed method would result in a lack of sufficiency of disclosure. Yet no objection on sufficiency of disclosure was raised by the appellant (see also section II. above).

22. Contrary to the appellant's view, step (iii) hence contributes, together with the technical steps (i) and (ii) of measuring the blood sCr and SDMA concentrations, to providing a method for estimating the clinical parameter GFR in an animal subject and hence contributes to the technical character of the claimed method.

Technical effect and objective technical problem

23. According to the patent, the product of the concentration values of sCr and SDMA allows for an improved estimation of the GFR compared to either concentration value alone (see paragraphs [0143] and [0148], Examples 6 and 7, and Figures 7 and 11 of the patent). However, as document D1 already suggests measuring the concentration values of both sCr and SDMA for the assessment of renal function (see the last paragraph of document D1 and point 14. above), an improvement over the method proposed in document D1 cannot be acknowledged.

24. The objective technical problem is therefore the provision of an alternative method for estimating the GFR.

25. The appellant contested that the objective technical problem could be formulated in this manner. The claim required that the standard values must be obtained in the same (individual) animal subject for which the GFR was to be estimated by the same measurements and calculations, which resulted in a "circular mathematical reasoning". According to the appellant, the objective technical problem was thus the provision of an alternative way of mathematically treating results obtained from measurements of blood samples from animal subjects.

26. The appellant's claim construction cannot be followed however. The expression "standard values that correlate to glomerular filtration rate in the animal subject" defines that these values are applicable to the animal subject for which the GFR is to be estimated, but not that these standard values have to be determined, first, in the same (individual) animal subject.

27. The appellant's assertion in this context that neither the claim nor the patent disclosed how the standard values recited in the claim could be obtained is not persuasive either, as the determination of such standard values lies within the skilled person's common general knowledge. Indeed, standard values for markers are commonly used in methods in which the concentration of a clinical marker is determined in a subject's sample and then compared to standard values of that clinical marker. The standard values are obtained from a population of healthy and/or diseased subjects, as is also described in paragraphs [0056] and [0057] of the patent, for example.

28. In this context, the appellant also referred to individual variations in the concentration of the markers, influenced by external factors, for instance. However, this fact is routinely taken into account by establishing the standard values from a representative population of subjects and expressing them as ranges and does not hinder the skilled person from establishing standard values for the product of the sCr and SDMA concentration values correlating to the GFR for a given animal species.

29. Moreover, Figure 7 of the patent discloses a standard curve that correlates the value of this product with GFR and that was established for the population of dogs analysed in Example 6. Example 7 of the patent discloses the same analysis for a population of cats (Figure 11). It is therefore incorrect that the patent does not teach the skilled person how to accurately determine standard values or that, as also asserted by the appellant, the standard values for the product of the sCr and SDMA concentration values are specific to each individual animal subject. According to Examples 6 and 7 of the patent, these standard values are species-specific, as would have been expected by the skilled person, and no evidence to the contrary was submitted by the appellant.

30. In this context, the appellant also objected to the fact that the patent did not explain why weighting factors P and Q (also recited in dependent claim 4) differed between Examples 6 and 7. However, since in these examples different species were analysed (dogs and cats), this difference is not surprising.

31. The appellant also pointed to the fact that Examples 6 and 7 of the patent disclose a retrospective analysis of measured data and do not assess the GFR in an animal subject that had not been used for establishing the standard curve. The board fails to understand how this observation is relevant to the assessment of inventive step of the claimed method. Examples 6 and 7 demonstrate that the product of the sCr and SDMA concentration values correlates better with the GFR than either concentration value alone and therefore provide proof of concept of the claimed method. It is not necessary for a patent's working examples to carry out the claimed method.

32. The appellant's assertions that the claim was based on a "circular mathematical reasoning", that the skilled person could not establish the required standard values for the product of the sCr and SDMA concentration values, and that the objective technical problem was the provision of an alternative way of mathematically treating results obtained from measurements of blood samples from animal subjects are therefore not persuasive.

Obviousness

33. Document D1 teaches that SDMA "might be a useful addition to sCr in the assessment of renal function" (see the last paragraph) and therefore proposes assessing renal function based on the serum concentrations of both sCr and SDMA. Document D1 is silent, however, on what the addition of SDMA to sCr could look like.

34. The sCr and SDMA concentration values are measured parameters, and not, contrary to the assertion of the appellant, probabilities. The board therefore cannot see how the theory of probabilities could be relevant to the measured parameters in the claim. The appellant's argument that it was obvious to use the product of the sCr and SDMA concentration values for estimating the GFR as these values were independent probabilities that could be multiplied together is speculative since it lacks any support from the prior art and is thus not persuasive.

35. Moreover, the board is not persuaded by the appellant's assertions that a ratio of SDMA and sCr concentration values fell under the expression "product" used in the claim and that the provision of the ratio of sCr and SDMA concentrations was obvious from Figure 2 on page 2451 of document D2, for example. The reason for this is that a ratio is the result of a division, which is a different mathematical operation than a multiplication resulting in a product. According to the common meaning of these expressions, the "ratio" of two values is hence not encompassed by the "product" of two values.

36. It is true that the patent discloses that weighting factors P and Q could be negative (see, for example, paragraph [0055]) and that the patent contemplates the relationship of the inverse of the product of the sCr and SDMA concentration values to the GFR (see, for example, Figure 8). However, paragraph [0055] merely teaches that both weighting factors can be negative, in which case the inverse of the product is obtained, but not that one weighting factor could be negative and the other one positive. The patent's description therefore does not teach that the expression "product" used in the claim could be a "ratio", contrary to the common meaning of these terms.

37. Consequently, document D2, which discloses the ratio but not the product of SDMA and sCr concentration values, cannot support the notion that it was obvious to estimate the GFR in an animal subject based on the product of the SDMA and sCr concentration values measured in a blood sample from the animal subject.

38. Thus, none of the appellant's arguments as to why the claimed method was obvious when selecting document D1 as the starting point for the assessment of inventive step are persuasive.

Document D6 as closest prior art

39. Similar considerations apply when selecting document D6 as the closest prior art instead of document D1. Document D6 discloses SDMA as an alternative diagnostic marker for sCr (see paragraphs [0006] and [0064], for example), but does not propose combining the SDMA and sCr blood concentrations in order to estimate the GFR and assess renal disease.

40. In view of this teaching in document D6 and the disclosure in paragraphs [0143] and [0148] of the patent that the product of the concentration values of sCr and SDMA allows for an improved estimation of the GFR compared to either concentration value alone (see also point 23. above), the technical effect of the claimed method compared to that in document D6 is an improved estimation of the GFR.

41. The technical problem to be solved thus resides in the provision of an improved method for estimating the GFR in an animal subject.

42. In view of the experimental data in Examples 6 and 7 of the patent, the board is satisfied that the method of claim 1 solves this problem.

43. Furthermore, as regards obviousness the employment of the product of the sCr and SDMA concentration values in order to achieve this effect was not obvious for the same reasons as those outlined above with respect to document D1 as the closest prior art (see points 34. to 37. above).

44. The claimed method hence involves an inventive step irrespective of whether document D1 or document D6 is used as the starting point and whether or not the teaching of document D2 is taken into account as well (Article 56 EPC).

45. None of the grounds for opposition that were admissibly raised by the appellant prejudices the maintenance of the patent as granted.